BackgroundThe 25-item Central Sensitisation Inventory (CSI-25) is a patient-reported instrument used to screen patients at risk of central sensitisation, a pathophysiological mechanism implicated in many chronic pain syndromes.AimsTo adapt and validate a Chinese version of the CSI-25 in the Chinese population.MethodsThe Chinese CSI-25 was developed by the translation of the original English version, back translation, cultural adaptation and revision using the Delphi method. The Chinese CSI-25 was administered to 237 patients with chronic pain and 55 healthy controls. Structural validity (confirmatory factor analysis), construct validity (correlations with other instruments), test–retest reliability and internal consistency were evaluated.ResultsConfirmatory factor analysis extracted four main factors (‘physical symptoms’, ‘emotional distress’, ‘headache/jaw symptoms’ and ‘urological symptoms’). The Chinese CSI-25 score was positively correlated with the Pain Catastrophic Scale (PCS) total score (r=0.709), PCS subscale scores (r=0.630–0.695), Brief Pain Inventory (BPI) mean item score (r=0.773), BPI total score (r=0.773) and the number of painful sites (r=0.636). The Chinese CSI-25 had excellent test–retest reliability (intragroup correlation coefficient=0.975) and good internal consistency (Cronbach’s α=0.930 in the overall population and 0.882 in the chronic pain population).ConclusionsThe Chinese CSI-25 had excellent test–retest reliability and satisfactory structural validity and construct validity. This instrument could potentially be used in China as a self-report questionnaire in both clinical practice and research settings.
Chronic pain affects more than 30% of the general population. The 9-item Central Sensitization Inventory (CSI-9) is a shortened version of the CSI-25, which is a patient-reported instrument used to screen people at risk of central sensitization (CS). The aim of this study was to cross-culturally adapt and validate a Chinese version of the CSI-9. The Chinese CSI-9 was generated by translation of the original English version, back-translation, cultural adaptation, and revision using the Delphi method. The Chinese CSI-9 was administered to 235 patients with chronic pain and 55 healthy controls. Structural validity (confirmatory factor analysis), construct validity (correlations with other scales), test-retest reliability (intraclass correlation coefficient, ICC), and internal consistency (Cronbach’s α) were evaluated. Confirmatory factor analysis was performed using one factor. The Chinese CSI-9 score was positively correlated with the Pain Catastrophic Scale (PCS) total score (r = 0.463), PCS subscale scores (r = 0.347–0.463), Brief Pain Inventory (BPI) mean item score (r = 0.524), BPI total score (r = 0.773), and the number of painful sites (r = 0.451). The Chinese CSI-9 had excellent test-retest reliability (ICC = 0.958) and excellent internal consistency (Cronbach’s α = 0.902 in the overall sample and 0.828 in the chronic pain population). The optimal cut-off value for the Chinese CSI-9 was 18 points. The Chinese CSI-9 had excellent test-retest reliability and satisfactory structural validity and construct validity. The CSI-9 could potentially be utilized in China as a self-report questionnaire in both clinical practice and research settings.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.